The NHS National Institute for Health Research has published a SIGNAL article highlighting a systematic review of 24 studies (including 5,454 people) investigating the value of self-monitoring of blood glucose by people with type 2 diabetes who are not treated with insulin. The NIHR SIGNAL concludes that “patients with type 2 diabetes who monitor their blood glucose themselves mayContinue Reading »
The Northern Treatment Advisory Group (NTAG) “recommends Freestyle Libre® as an option for glucose monitoring in Type 1 diabetic patients only in the North East and Cumbria for patients who fulfil the Regional Medicines Optimisation Committee criteria.” The NTAG position statement also states that FreeStyle Libre “…….. should not be prescribed in primary care and should only be initiated and prescribed byContinue Reading »
The updated guideline now includes text on sodium–glucose cotransporter 2 (SGLT-2) inhibitors in the section on initial drug treatment. Additionally, new information on SGLT-2 inhibitors was added to the box on action to take if metformin is contraindicated or not tolerated.
Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes.